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ABSTRACT
Introduction: Debridement and prosthesis
retention, combined with a prolonged
antibiotic regimen including rifampicin, is an
accepted therapeutic approach when the
duration of symptoms is less than 4 weeks and
there are no radiological signs of loosening. The
outcome of patients managed with this strategy
has been previously assessed in several articles
with success rates of 60–90%. This study aims to
review the clinical experience with linezolid in
3 different hospitals from Spain and France in
patients with prosthetic joint infection (PJI)
managed with debridement, retention of the
implant and treated with linezolid with or
without rifampicin.
Methods: Patients with an acute PJI who
underwent open debridement with implant
retention treated with linezolid for more than
7 days in 3 hospitals from Barcelona, Tours
and Lille between 2005 and 2011 were
retrospectively reviewed. Relevant information
about demographics, co-morbidity, type of
implant, surgical treatment, microorganism
isolated, antimicrobial therapy, adverse events
(AEs) and outcomes were recorded from
patients.
Results: A total of 39 patients were
retrospectively reviewed. The mean age (SD)
was 70.5 (8.8) years and 9 patients had diabetes
mellitus (23%). There were 25 (64%) knee
prostheses, 13 (33%) hips and 1 shoulder (3%).
The median interquartile range (IQR) days from
arthroplasty to infection diagnosis was 17
(19–48) and 33 (85%) cases were diagnosed
within the first 60 days. The median (IQR)
duration of antibiotic treatment was 70.5
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(34–96) days and the median (IQR) number of
days on linezolid treatment was 44.5 (30–81).
AEs were observed in 15 patients (38%), with
gastrointestinal complaints in 8 cases and
anemia in 5 being the most frequent. After a
median (IQR) follow-up of 2.5 (1.8–3.6) years,
there were 11 failures (28%) (8 relapses and 3
new infections). The failure rate was higher in
the rifampicin group (36% vs. 18%) mainly due
to a higher relapse rate (27% vs. 12%) although
differences were not statistically significant.
Conclusion: Management of acute PJIs with
debridement and retention of the implant
linezolid, with or without rifampicin, is
associated with a high remission rate and it is
an alternative treatment for infections due to
fluoroquinolone and/or rifampicin-resistant
staphylococci.
Keywords: Debridement; Infectious diseases;
Linezolid; Prosthetic joint infection;
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INTRODUCTION
Debridement and prosthesis retention,
combined with a prolonged antibiotic regimen
including rifampicin, is an accepted therapeutic
approach when the duration of symptoms is less
than 4 weeks and there are no radiological signs
of loosening. The outcome of patients managed
with this strategy has been previously assessed
in several articles with success rates between
60% and 90% [1–6]. The best results have been
reported when rifampicin was associated with
fluoroquinolones [4, 5]; however, the rate of
multi-resistant staphylococci, including
fluoroquinolones, is high and therefore, oral
antibiotic alternatives are necessary. Linezolid
has a 100% oral bioavailability and reaches high
concentrations in musculoskeletal tissues (skin,
synovial fluid and bone) [7–9]; therefore, it is an
attractive oral alternative and some data from
experimental foreign-body infection model
showed good results [10]. Recently, two studies
performed in healthy volunteers have analyzed
the interaction between linezolid and
rifampicin after 3 days of combined therapy
[11, 12]. Both articles support the interaction
and found a reduction of about 30% in the area
under the concentration–time curve (AUC) of
linezolid. In addition, 2 cases of orthopedic
implant infections where this combination
was associated with low linezolid serum
concentrations and clinical failure have been
described [13]. However, the clinical experience
with this combination is still scarce.
The aim of the present study was to
retrospectively review the clinical experience
with linezolid in 3 different hospitals from
Spain and France in a particular group of
patients with a prosthetic joint infection (PJI),
who underwent open debridement with
retention of the implant, whilst being treated
with linezolid with or without rifampicin.
METHODS
Study Design
A retrospective observational study was
performed in 3 hospitals from Barcelona,
Tours and Lille between 2005 and 2011. All
patients included had an acute PJI, were treated
with an open debridement with implant
retention and received linezolid for more than
7 days. Relevant information about
demographics, co-morbidity, type of implant,
surgical treatment, microorganism isolated,
antimicrobial therapy, adverse events (AEs)
and outcomes were recorded. Linezolid dose
was 600 mg/12 h. When rifampicin was added,
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the dose varied from 600 mg/24 h to 10 mg/kg/
12 (not exceeding 900 mg/12 h). In case of
polymicrobial infection, ciprofloxacin or a
b-lactam were added according to the Gram-
negative antibiogram.
Compliance with Ethics Guidelines
This study was approved by the Ethics
Committee of our institution.
This article does not involve any new studies
of human or animal subjects performed by any
of the authors.
Definitions
PJIs were defined by the presence of local
inflammation, macroscopic evidence of
extension of the infection through the capsule
during open debridement, and isolation of
significant microorganisms from deep samples.
In the case of coagulase-negative staphylococci,
C2 positive deep samples were required for
considering this microorganism a true
pathogen. The infection was considered acute
when it occurred within 4 weeks after the
arthroplasty (early post-operative infection) or
after 4 weeks with acute onset of symptoms
(late acute infection).
Hematological toxicity was defined as a
[2 g/L decrease in the basal hemoglobin
concentration without another plausible
explanation.
Outcome was classified according to the
following definitions: (1) remission, when the
patient had no symptoms of infection, the
C-reactive protein (CRP) was \1 mg/dl and the
prosthesis was retained after at least 1 year of
follow-up; or (2) failure, when inflammatory
signs and high CRP reappear during or after
treatment. Failure was divided into relapsed or
new infection according to the isolated
microorganism. If the isolated microorganism
was the same it was considered as relapsed, and
when the microorganism was different, it was
considered as reinfection. It was not considered
failure when the patient developed an aseptic
loosening that required the prosthesis to be
exchanged and deep samples taken during
surgery were negative.
Statistical Analysis
Categorical variables were described as
percentage and continuous variables as
median and interquartile range (IQR).
Categorical variables were compared by Chi-
square test or Fisher’s exact test when necessary
and continuous variables by Mann–Whitney
U test. The Kaplan–Meier survival method was
used to estimate the cumulative probability of
being in remission in the last visit in those
patients receiving or not receiving rifampicin.
The Log-Rank test was applied to evaluate the
influence of rifampicin. Statistical significance
was defined as a two-tailed P\0.05. The
analysis was performed using SPSS, version
20.0 (SPSS, Inc., Chicago, IL, USA).
RESULTS
A total of 39 patients were retrospectively
reviewed. The mean age (SD) was 70.5 (8.8)
years, 21 were females (54%) and 9 patients had
diabetes mellitus (23%). There were 25 (64%)
knee prostheses, 13 (33%) hips and 1 shoulder
(3%). Only 4 (10%) were late acute infections.
The median (IQR) days from arthroplasty to
infection diagnosis was 17 (19–48) and 33 (85%)
cases were diagnosed within the first 60 days.
Infections were monomicrobial in 24 (62%)
cases and polymicrobial in 15 (38%), and the
isolated microorganisms are described in
Table 1. The median (IQR) number of days on
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linezolid treatment was 44.5 (30–81) and the
median (IQR) duration of all antibiotic
treatment was 70.5 (34–96) days, including
treatment for microorganisms not covered by
linezolid in polymicrobial infections. AEs were
observed in 15 patients (38%), with
gastrointestinal complaints (nausea, vomiting
or diarrhea) in 10 cases and hematological
toxicity in 5 cases the most frequent. There
were 11 failures (28%) including 8 (21%)
relapses and 3 new infections (8%). Therefore,
28 patients (72%) were in remission after a
median (IQR) follow-up of 2.5 (1.8–3.6) years
from stopping antibiotic treatment.
In 22 patients (56%) rifampicin was given
concomitantly with linezolid and 17 did not
receive rifampicin because of resistance or
drug interaction (i.e., acenocoumarol). The
characteristics of patients according to
whether or not they received rifampicin are
shown in Table 2. Although no difference
between both groups was statistically
significant, patients receiving rifampicin had a
higher rate of diabetes mellitus (27% vs. 18%), a
longer duration of symptoms before open
debridement (9 vs. 2 days), and all MRSA
infections were recorded in the rifampicin
group (5 vs. 0). The remission rate was lower
in the rifampicin group (64% vs. 82%, P = 0.28)
due to a higher relapse rate (27% vs. 12%).
There were 9 infections due to Staphylococcus
aureus, 8 cases (including the 5 MRSA infections
in the rifampicin group) were considered in
remission (89%) and 1 patient had a new
infection. In contrast, 15 out of 26 infections
were due to coagulase-negative staphylococci.
CoNS were in remission (58%) and 7 (27%)
were due to infection relapse. The cumulative
probability of being in remission in the last visit
in patients receiving or not rifampicin is shown
in Fig. 1 (Log-Rank test, P = 0.25). There were
no differences in the total number of AEs
between both groups; however,
gastrointestinal complains were more frequent
in the rifampicin group (32% vs. 18%) while
hematological toxicity was more frequent in the
group without rifampicin (24% vs. 5%).
DISCUSSION
An alternative agent for treating PJIs due to
fluoroquinolone-resistant staphylococci is
necessary [14]. In the present study, acute PJIs
were managed with debridement, retention of
the implant and linezolid with a remission rate
of 72% and when considering only relapses
(isolation of the same species), it was 80%.
These results are similar to those presented by
Bassetti et al. [15] using the same surgical
strategy and linezolid alone in 20 PJIs with a
Table 1 Isolated microorganisms in 39 cases of prosthetic
joint infection
Microorganism Number (%)a
Staphylococcus aureus 9 (17)
Methicillin-susceptible 4
Methicillin-resistant 5
Coagulase-negative staphylococci 33 (61)
Methicillin-susceptible 10
Methicillin-resistant 23
Enterococcus faecalis 4 (7)
Streptococcus viridans 2 (4)
Enterobacteriaceaeb,c 5 (9)
Pseudomonas aeruginosac 1 (2)
a The percentage is referred to the total number of
isolated microorganisms (n = 54) that sum more than 39
because 15 patients had a polymicrobial infection
b Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis,
Citrobacter freundii and Enterobacter cloacae
c These microorganisms were always part of a
polymicrobial infection with other Gram-positive
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rifampicin (n 5 17)
P
Median (IQR) age 71 (63–75) 75 (66–77) 0.31
Male sex (%) 9 (41) 9 (53) 0.45
Diabetes mellitus (%) 6 (27) 3 (18) 0.37
Type of implant (%) 0.50
Hip prosthesis 7 (32) 6 (35)
Knee prosthesis 15 (68) 10 (59)
Shoulder prosthesis – 1 (6)
Age of prosthesis 30 (21–55) 24 (17–32)
Late acute infections (%) 2 (9) 2 (12) 1
Median (IQR) days of symptoms before debridement 9 (3–25) 2 (1–22) 0.14
Fever (%) 3 (14) 2 (12) 1
Bacteremia (%) 2 (9) 1 (6) 1
Median (IQR) leukocyte count (cells/mm3) 8,400 (6,400–9,600) 6,950 (5,750–8,125) 0.18
Median (IQR) C-reactive protein (mg/dL) 4 (2–11) 3 (1–5) 0.22
Microorganisms
S. aureus (MR) 6 (5) 3 (0)
CoNS (MR) 18 (13) 15 (10)
E. faecalis 3 1
S. viridans 1 1
Enterobacteriaceae 2 3
P. aeruginosa 1 –
Polymicrobial (%) 9 (41) 6 (35) 0.50
Adverse events 9 (41) 8 (47)
Gastrointestinal (nausea, vomits or diarrhea) 7 (32) 3 (18)a
Hematological toxicity 1 (5) 4 (24)
Peripheral neuropathyb 1 (5) 1 (6)
Outcome (%)
Remission 14 (64) 14 (82) 0.28
Relapse 6 (27) 2 (12)
New infection 2 (9) 1 (6)
Infect Dis Ther (2014) 3:235–243 239
remission rate of 80% and 20% of relapsing
infections. Monotherapy with linezolid was also
evaluated by Rao et al. [16] in 11 cases with a
remission rate of 95%. Although the experience
is limited, these results are in contrast to the
23% remission rate described using intravenous
vancomycin in MRSA PJI treated with retention
of the implant [17] and it suggests that linezolid
could be an alternative for infections due to
multi-resistant staphylococci.
The addition of rifampicin to linezolid would
be reasonable [18, 19], particularly when the
foreign-body is not removed, due to the potent
activity of rifampicin against biofilm bacteria [4,
20]. It has been demonstrated that rifampicin
reduces about 30% the AUC of linezolid [11, 12];
however, the clinical implication of this
interaction is not well established. This
combination was assessed in a retrospective
study that reviewed 28 osteomyelitis and
Fig. 1 The cumulative probability of being in remission according to whether the patient received concomitant rifampicin





rifampicin (n 5 17)
P
Median (IQR) days of follow-up from stopping
antibiotics to the last visit
730 (161–1,219) 812 (618–1,362) 0.39
IQR interquartile range, MR methicillin-resistant
a 2 patients also develop hematological toxicity, therefore, the total number of patients with at least 1 adverse event was 15
(38%)
b Patients developed peripheral neuropathy during the last few days of the treatment
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orthopedic implant infections [21]. The success
rate was 89.2%, however, only 4 cases were
managed without removing the implant. In
contrast, Gomez et al. [22] showed a success rate
of 69% but, in this series, all patients were
managed with implant retention and
rifampicin. In our cohort, no statistically
significant difference was observed in the
success rate between those patients receiving or
not receiving rifampicin but slightly worse results
among those receiving rifampicin were observed.
This finding could be explained, at least in part,
because these patients had a higher rate of
diabetes mellitus (32% vs. 18%), and a longer
duration of symptoms before open debridement
(9 days vs. 2 days), variables that have been
associated with a higher failure rates [23]. MRSA
infections were all in the group of rifampicin and
all achieved remission; therefore, this difference
cannot explain the difference between the 2
groups. In addition, it is not possible to rule out
a low linezolid concentration in the rifampicin
group as an additional explanation. Linezolid is a
time-dependent antibiotic [24]; therefore, the
pharmacodynamic target is to maintain a
trough serum concentration around 2 times
over the minimum inhibitory concentration
(MIC). Since the MIC90 for Gram-positive
staphylococci is 2 mg/L [25], the optimal trough
level will be 4 mg/L, a concentration that also it
has been associated with low risk of toxicity [26],
which is the major concern when linezolid is
administered for prolonged time. These results
suggest that monitoring trough serum
concentration could be useful for improving the
outcome, most especially when linezolid is
combined with rifampicin, and for avoiding
toxicity in patients that require prolonged
treatment [27]. Indeed, hematological toxicity
was more frequent in the monotherapy group
(24% vs. 5%) probably due to the higher linezolid
concentrations.
The main drawbacks of this study are the
low number of patients, the retrospective
design, that clonal relationship between
microorganism isolated in primary and
relapse episodes was not performed in order
to confirm the relapse rate and the fact that
linezolid concentrations were not measured;
however, the information reported is useful to
improve the results in PJIs due to resistant
staphylococci.
CONCLUSION
Acute PJIs managed with debridement and
retention of the implant linezolid, with or
without rifampicin, are associated with a
high remission rate and this is therefore an
alternative therapy for infections due to
fluoroquinolone and/or rifampicin-resistant
staphylococci. However, prolonged linezolid
may have important AEs that require
close monitoring by infectious diseases
physicians.
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